Regencell Bioscience Holdings Ltd Cash And Cash Equivalents At Carrying Value

Quick Answer

Regencell Bioscience Holdings Ltd reported Cash And Cash Equivalents At Carrying Value of $6.42 million for the year ending 2022.

  • Regencell Bioscience Holdings Ltd showed an increase of +10,700.7% in Cash And Cash Equivalents At Carrying Value from 2021 to 2022.
  • This data is from Regencell Bioscience Holdings Ltd's annual report (Form 10-K), filed with the SEC on October 31, 2022.
  • XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2018 to 2022), Regencell Bioscience Holdings Ltd's Cash And Cash Equivalents At Carrying Value has grown by 4,085.8%.
  • Historical annual values: Fiscal year 2022: $6.42 million | Fiscal year 2021: $59.4 thousand | Fiscal year 2020: $387.0 thousand | Fiscal year 2019: $243.3 thousand | Fiscal year 2018: $153.3 thousand.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: